Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan ― An Interrupted Time Series Analysis ―
Circulation Reports · 10.11.2026 · 8 (11) · 1819-1826
DOI: 10.1253/circrep.cr-26-0142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Circulation Reports, erschienen am 10.11.2026. Verfasst von Ryosuke Miura und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital Sendai Japan. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Sodium-glucose co-transporter 2 (SGLT2) inhibitors and loop diuretics have beneficial diuretic effects in patients with heart failure but may increase the risk of excessive water loss. Therefore, clinical guidelines recommend adjustment of loop diuretic doses when these agents are used concomitantly. However, real-world evidence regarding changes in loop diuretic dosing is limited. This study evaluated changes in prescribed doses of oral loop diuretics in patients with heart failure receiving dapagliflozin or empagliflozin before and after publication of the JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Methods and Results: Changes in prescribed dose trends were evaluated using monthly aggregated prescription data obtained from the Medical Data Vision database (Medical Data Vision, Inc., Tokyo, Japan). After publication of the guideline, statistically significant decreases were observed in the empagliflozin-prescribed group for azosemide (-0.1756 mg/month; P=0.0360), furosemide (-0.2180 mg/month; P=0.0485), and torsemide (-0.0387 mg/month; P=0.0378), and in the dapagliflozin-prescribed group for azosemide (-0.8221 mg/month; P=0.0260). The study period for dapagliflozin was too short to provide adequate statistical power.
Conclusions
The publication of the JCS/JHFS 2021 guideline was associated with decreases in prescribed doses of oral loop diuretics. Dose reduction of oral loop diuretics may be considered in patients receiving concomitant SGLT2 inhibitors in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Tohoku Medical and Pharmaceutical University Hospital Sendai Japan.
- Division of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University Sendai Japan.
Zitieren
APA
Miura, R., & Okada, K. (2026). Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan ― An Interrupted Time Series Analysis ―. Circulation Reports, 8(11), 1819-1826. https://doi.org/10.1253/circrep.cr-26-0142
Vancouver
Miura R, Okada K. Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan ― An Interrupted Time Series Analysis ―. Circulation Reports. 2026;8(11):1819-1826. doi:10.1253/circrep.cr-26-0142
BibTeX
@article{Miura2026,
author = {Miura, Ryosuke and Okada, Kouji},
title = {Trends in the Prescribed Doses of Loop Diuretics in Patients With Heart Failure Prescribed Dapagliflozin or Empagliflozin in Japan ― An Interrupted Time Series Analysis ―},
journal = {Circulation Reports},
year = {2026},
volume = {8},
number = {11},
pages = {1819--1826},
doi = {10.1253/circrep.cr-26-0142}
}
EUVIMED